|
Condition
|
Cost per patient
|
Effectiveness
|
ICERa
|
NMBb
|
|---|
|
Utility: QALYS
|
|
Baseline (REP only)
|
588.95
|
0.47
|
0
|
46911.05
|
|
REP+EF only
|
637.53
|
0.48
|
Dominatedc
|
47822.00
|
|
REP+EF, add IF if needed
|
627.40
|
0.54
|
593.42d
|
53351.18
|
|
REP+EF/IF
|
625.95
|
0.47
|
Dominatedc
|
45987.68
|
- aICER: incremental cost-effectiveness ratio
- bNMB: net monetary benefit. Willingness-to-pay threshold $100,000/QALY [45]
- cDominated: more expensive and less effective than comparators [46]
- dSince “REP+EF/IF” is dominated, “REP+EF, add IF if needed” is compared to REP only
